ASCO 2025: Multiple Domestic New Drugs Reveal Impressive Clinical DataASCOASCO 2025 highlights impressive clinical data from multiple domestic new drugs including Kelun Biotech's sacituzumab govitecan, Mabwell's 9MW2821, Zelgen Bio's ZG006, and Hengrui's SHR-1501, showing promising efficacy and safety.
ASCO 2025: Innovent, RemeGen, Kelun Showcase Together!ASCOASCO 2025 highlights: Leading Chinese biotech companies Xinda, Rongchang, and Kelun present innovative clinical trial data on ADCs, bispecific antibodies, and targeted therapies, showcasing China's rising role in oncology innovation.
ASCO 2025: Most-Viewed AbstractsASCODiscover the top 4 most viewed abstracts at ASCO 2025, including updates on zanidatamab, talazoparib, GFH375, and Ziftomenib across gastric, prostate, solid tumors, and AML research.
Top 10 Best-Selling Drugs in Q1 2025Market TrendDiscover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
Pharma's $158B U.S. Manufacturing SurgeMarket TrendMajor pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
Q1 Sales Surge for CAR-T Therapies: Up to 146%Market TrendGuideView reviews the Q1 2025 sales performance of six FDA-approved CAR-T cell therapies. Highlights include Breyanzi’s 146% surge and Carvykti’s 135% rise, while Kymriah and Tecartus saw declines.
Takeda's 2024 Financial reportMarket TrendTakeda projects $11B in peak sales from three key drug candidates—TAK-279, TAK-861, and TAK-121—while restructuring its pipeline to drive future growth and profitability.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
